Physician profile
Varun Thapar
NPI 1790212892
$1,048.82
in general payments reported to CMS, 2019-2025
17 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $677 · 2022: $179 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $192.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.99 | 2021-2025 | Jardiance |
| Intuity Medical INC | $151.10 | 2022 | |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Boston Scientific Corporation | $123.84 | 2021 | |
| Sanofi-Aventis U.S. LLC | $120.69 | 2021 | |
| Exact Sciences Corporation | $62.84 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $57.68 | 2021 | |
| Novo Nordisk INC | $52.46 | 2025 | Wegovy |
| Almatica Pharma LLC | $28.58 | 2025 | Teriparatide |
| Abbvie INC. | $28.33 | 2022 | |
| Merck Sharp & Dohme LLC | $26.57 | 2021 | |
| Astellas Pharma US INC | $24.86 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.43 | 2021 | |
| Dynavax Technologies Corporation | $19.86 | 2021 | |
| Abbott Laboratories | $17.76 | 2025 | Proclaim |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $15.86 | 2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $13.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varun Thapar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.